1. Home
  2. HURN vs ADPT Comparison

HURN vs ADPT Comparison

Compare HURN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huron Consulting Group Inc.

HURN

Huron Consulting Group Inc.

HOLD

Current Price

$131.11

Market Cap

2.9B

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$15.62

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HURN
ADPT
Founded
2002
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.8B
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
HURN
ADPT
Price
$131.11
$15.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$215.50
$17.20
AVG Volume (30 Days)
236.8K
1.9M
Earning Date
02-24-2026
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
32.32
N/A
EPS
5.98
N/A
Revenue
$1,618,977,000.00
$276,976,000.00
Revenue This Year
$14.19
N/A
Revenue Next Year
$9.49
$23.05
P/E Ratio
$24.39
N/A
Revenue Growth
12.67
54.77
52 Week Low
$120.25
$6.26
52 Week High
$186.78
$20.76

Technical Indicators

Market Signals
Indicator
HURN
ADPT
Relative Strength Index (RSI) 19.70 35.51
Support Level $158.00 $15.07
Resistance Level $176.10 $17.98
Average True Range (ATR) 7.77 1.16
MACD -4.09 -0.40
Stochastic Oscillator 3.11 13.13

Price Performance

Historical Comparison
HURN
ADPT

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Share on Social Networks: